39-17-410 - Controlled substances in Schedule III.
39-17-410. Controlled substances in Schedule III.
(a) Schedule III consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.
(b) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, positional or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under 21 CFR 1308.32, and any other drug of the quantitative composition shown in that list for those drugs or that is the same except that it contains a lesser quantity of controlled substances;
(2) Benzphetamine;
(3) Chlorphentermine;
(4) Clortermine; and
(5) Phendimetrazine.
(c) Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system:
(1) Any compound, mixture, or preparation containing:
(A) Amobarbital;
(B) Secobarbital;
(C) Pentobarbital;
or any salt thereof and one (1) or more other active medicinal ingredients that are not listed in any schedule;
(2) Any suppository dosage form containing:
(A) Amobarbital;
(B) Secobarbital;
(C) Pentobarbital;
or any salt of any of these drugs and approved by the United States food and drug administration for marketing only as a suppository;
(3) Any substance that contains any quantity of a derivative of barbituric acid or any salt thereof;
(4) Chlorhexadol;
(5) [Deleted by 2007 amendment.]
(6) Lysergic acid;
(7) Lysergic acid amide;
(8) Methyprylon;
(9) Sulfondiethylmethane;
(10) Sulfonethylmethane; or
(11) Sulfonmethane;
(12) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application of § 505 of the federal Food, Drug, and Cosmetic Act, codified in 21 U.S.C. § 355;
(13) Tiletamine and zolazepam or any salt of tiletamine or zolazepam;
(A) Another trade or other name for a tiletamine-zolazepam combination product: Telazol;
(B) Another trade or other name for tiletamineis 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
(C) Other trade or other names for zolazepam are 4-(2-fluorophenyl)-6,8- dihydro-1,3,8-trimethylpyrazolo-[3,4-e], [1,4]-diazepin-7(1H)-one and flupyrazapon.
(d) Nalorphine.
(e) Narcotic Drugs.
(1) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities:
(A) Not more than one and eight tenths (1.8) grams of codeine per one hundred (100) milliliters or not more than ninety (90) milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
(B) Not more than one and eight tenths (1.8) grams of codeine per one hundred (100) milliliters or not more than ninety (90) milligrams per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(C) Not more than three hundred (300) milligrams of dihydrocodeinone per one hundred (100) milliliters or not more than fifteen (15) milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
(D) Not more than three hundred (300) milligrams of dihydrocodeinone per one hundred (100) milliliters or not more than fifteen (15) milligrams per dosage unit, with one (1) or more active nonnarcotic ingredients in recognized therapeutic amounts;
(E) Not more than one and eight tenths (1.8) grams of dihydrocodeine per one hundred (100) milliliters or not more than ninety (90) milligrams per dosage unit, with one (1) or more active nonnarcotic ingredients in recognized therapeutic amounts;
(F) Not more than three hundred (300) milligrams of ethylmorphine per one hundred (100) milliliters or not more than fifteen (15) milligrams per dosage unit with one (1) or more active nonnarcotic ingredients in recognized therapeutic amounts;
(G) Not more than five hundred (500) milligrams of opium per one hundred (100) milliliters or per one hundred (100) grams or not more than twenty-five (25) milligrams per dosage unit, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts; or
(H) Not more than fifty (50) milligrams of morphine per ten (10) milliliters or per one hundred (100) grams, with one (1) or more active, nonnarcotic ingredients in recognized therapeutic amounts.
(2) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts: Buprenorphine.
(f) Anabolic steroids. Unless specifically excepted or unless listed in another schedule, any drug or hormonal substance, chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promotes muscle growth, and includes:
(1) Boldenone;
(2) Chlorotestosterone;
(3) Clostebol;
(4) Dehydrochlormethyltestosterone;
(5) Dihydratestosterone;
(6) Drostanolone;
(7) Ethylestrenol;
(8) Fluoxymesterone;
(9) Formebulone;
(10) Mesterolone;
(11) Methandienone;
(12) Methandranone;
(13) Methandriol;
(14) Methandrostenolone;
(15) Methenolone;
(16) Methyltestosterone;
(17) Mibolerone;
(18) Nandrolone;
(19) Norethandrolone;
(20) Oxandrolone;
(21) Oxymesterone;
(22) Oxymetholone;
(23) Stanolone;
(24) Stanozolol;
(25) Testolactone;
(26) Testosterone;
(27) Trenbolone; and
(28) Any salt, ester, or isomer of a drug or substance described or listed in this subsection (f), if such salt, ester, or isomer promotes muscle growth.
(g) (1) Except as provided in subdivision (g)(2), subsection (f) shall not be construed to include an anabolic steroid that is expressly intended for administration through implants to cattle or other nonhuman species and that has been approved by the United States secretary of health and human services for such administration. Also, except as provided in subdivision (g)(2), subsection (f) does not include an anabolic steroid that is a combination of estrogen with anabolic steroid and that is expressly intended for administration to hormone deficient women.
(2) If any person prescribes, dispenses, or distributes a steroid described in subdivision (g)(1) for human use, that person shall be considered to have prescribed, dispensed, or distributed an anabolic steroid within the meaning of subsection (f). If any person prescribes, dispenses, or distributes an anabolic steroid that is a combination of estrogens with anabolic steroid and that is intended for administration to hormone deficient women, for use by persons who are not hormone deficient women, that person shall be considered to have prescribed, dispensed or distributed an anabolic steroid within the meaning of subsection (f).
(h) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of ketamine hydrochloride, including its salts:
Ketamine hydrochloride.
(i) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved drug product.
[Acts 1989, ch. 591, § 1; 1992, ch. 700, § 3; 1996, ch. 694, §§ 1, 2; 2000, ch. 755, § 2; 2000, ch. 884, § 2; 2007, ch. 298, §§ 8-10.]